LPT
MRNA icon

Legacy Private Trust’s Moderna MRNA Stock Holding History

Legacy Private Trust’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,872
Closed -$793K – 246
2024
Q3 		$793K Sell
11,872
-5,465
-32% -$502K 0.05% 159
2024
Q2 		$2.06M Sell
17,337
-2,225
-11% -$282K 0.15% 111
2024
Q1 		$2.08M Buy
19,562
+3,637
+23% +$367K 0.15% 111
2023
Q4 		$1.58M Buy
15,925
+10,865
+215% +$914K 0.13% 123
2023
Q3 		$523K Sell
5,060
-1,687
-25% -$188K 0.05% 170
2023
Q2 		$820K Buy
6,747
+904
+15% +$121K 0.07% 143
2023
Q1 		$897K Buy
+5,843
New +$964K 0.08% 141
2022
Q3 		– Sell
-1,459
Closed -$208K – 227
2022
Q2 		$208K Sell
1,459
-1,070
-42% -$153K 0.02% 215
2022
Q1 		$436K Sell
2,529
-411
-14% -$69.2K 0.03% 200
2021
Q4 		$746K Buy
2,940
+2,165
+279% +$633K 0.06% 168
2021
Q3 		$298K Buy
+775
New +$286K 0.02% 204

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Legacy Private Trust's MRNA Position: Q4 2024 in Review

Legacy Private Trust sold out of Moderna (MRNA) in Q4 2024, closing a stake of 11,872 shares — an estimated $793K sold.

Legacy Private Trust first reported a position in MRNA in Q3 2021 and held it in 11 quarters. The position peaked at $2.08M in Q1 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Legacy Private Trust reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Legacy Private Trust sold 11,872 Moderna shares in Q4 2024, an estimated $793K.
  • Legacy Private Trust first reported a position in Moderna in Q3 2021 and held it in 11 quarters.
  • Legacy Private Trust's Moderna position peaked at $2.08M in Q1 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Legacy Private Trust's 13F filing for Q4 2024, filed 8 Jan 2025.